Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.

Eli Lilly alleges Willow falsely claims its products are safe, effective and superior to its FDA-approved tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes, and ...

A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes medication Ozempic.

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

Zepbound (tirzepatide) is a weekly injectable weight-loss medication. It can be purchased online or in person with a valid ...

Sven Knudsen Ljaamo, MD, a Veterans Affairs' physician in Massachusetts, was charged with possessing child sexual abuse ...

Global Data has revealed that the Top 20 Global Biopharmaceutical Companies have witnessed a 6 % growth in market ...

A Houston-based compounding pharmacy that was recently roped into Eli Lilly’s fight against knockoff GLP-1s has landed in the ...

But recent weak U.S. prescription data is leading some investors and analysts to question whether that stellar run, which ...

White House advisors are mulling over ways to increase the birth rate, including a $5,000 "baby bonus" to mothers. (ABC News) ...